Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
$111.09 - $169.37
Next Earnings Date
May 01 2025
Next Earnings Date
May 01 2025
Latest price
Market Cap | $9.51B |
EV | $9.82B |
Shares Outstanding | 62.19M |
Beta | 0.54 |
Analyst Rating | BUY |
Analyst Target Price | $212.97 |
P/E 2025E | - |
P/Revenue 2025E | 14.31x |
Revenue | 249.10% |
EPS | 5.30% |
Operating Cash Flow | 12.60% |
Free Cash Flow | 14.10% |
Revenue | 66.90% |
EPS | - |
Operating Cash Flow | - |
Free Cash Flow | - |
Gross Margin 2025E | 86.86% |
Net Profit Margin 2025E | -32.14% |
ROE 2025E | -2313.53% |
ROCE 2024 | - |
DPS 2025E | $0.00 |
Payout Ratio 2025E | 0.00% |
Div. Yield 2025E | 0.00% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Ascendis Pharma A/S
ASND
Sector
Healthcare
Industry
Biotechnology
CEO
Mikkelsen, Jan
Employees
1,017
Website
ascendispharma.comIPO Date
2015-01-28
Headquarters
Tuborg Boulevard 12, Hellerup, Capital Region of Denmark, 2900, Denmark
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved